THERAPY DOSSIER · th-2fe4b11e8392

Recombinant human bone morphogenetic protein-2 on absorbable collagen sponge

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00853489 ↗Injury indicationPHASE4terminated

rhBMP-2 vs Autograft for Critical Size Tibial Defects

Tibial Fractures

Enrolment: 33 · Results not recorded

NCT05405374 ↗NAunknown

OSTEOAMP SELECT Fibers vs Infuse (rhBMP-2) Bone Graft in Lumbar Fusion

Degenerative Disc Disease

Enrolment: 101 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30805987 ↗2019No effect reported

Sub-clinical dose of bone morphogenetic protein-2 does not precipitate rampant, sustained inflammatory response in bone wound healing.

MouseWoundC57BL/6 wild-type (Jackson Laboratory)Mixed sexn = 48 mice total, evenly distributed across two surgical group…Local implantation into the calvarial defect325 ng rhBMP-2 per defect, loaded on absorbable collagen sp…At the time of defect creation

Model: 5 mm critical-size calvarial (craniectomy) defect

A sub-clinical rhBMP-2 dose produced only transient modulation of inflammatory markers that largely resolved to control levels by 7 days, with reduced MCP-1, IL-12 and IL-1beta and increased TNF-alpha, IL-13, VEGF and FGF at 3 days. Cellular infiltrate was significantly increased at 3 and 7 days, F…

Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…